• Home icon
  • LinkedIn icon

When Your CDMO’s Own Workforce Walks Out, Who Carries the Risk?

Insights by Mark Davis, Senior Director, CDMO, Danforth Health

The ongoing labor dispute at Samsung Biologics is a useful stress test for every sponsor that relies on a single CDMO. On November 6, the union began a three-week partial strike, the latest action in a dispute running since spring. A disruption isn’t certain. But most sponsors haven’t checked what their contract says if one happens.

The clause that matters most is one few people reread: Force Majeure.

The clause that decides who waits

CDMO legal teams draft Force Majeure as broadly as they can. Many list “labor disturbances and strikes” without separating the CDMO’s own workforce from third parties. That distinction is everything.

If your CDMO’s internal labor dispute counts as Force Majeure, its affected delivery obligations may be excused for as long as the event lasts. Your remedy may be limited to termination after a set period.

Termination doesn’t recover the millions you’ve spent on tech transfer, process development, and validation. And it doesn’t put your clinical program back on schedule.

Why small sponsors feel it first

Now imagine a partial disruption. Production slows but doesn’t stop, and capacity is scarce. Who gets priority: commercial customers generating hundreds of millions in recurring revenue, or a Phase 1/2 program worth a handful of batches?

We don’t know how any CDMO would allocate. But the incentives are obvious. Clinical-stage biotechs also tend to run lean inventories, with batches tied to patient dosing and financing milestones. A delayed batch can mean postponed dosing, months lost, extra cash burn, and a missed milestone.

The customer least able to tolerate a delay may have the least say in who gets delayed.

What you can do now

If your agreement is already signed, you still have options. Your leverage is lower than it was before signing, but it isn’t zero. It shrinks the longer you wait.

  1. Read your Force Majeure clause with one question in mind. Does it excuse the CDMO’s own labor disputes, or only third-party events? What notice, mitigation, and duration limits apply?
  2. Know what you own. Confirm who controls the cell bank, process improvements, manufacturing know-how, and batch records. Check whether the CDMO is obligated to support a transfer.
  3. Check your delivery and remedy terms. Are delivery commitments clearly defined? Does the agreement separate no-fault from at-fault failures, and can you recover sunk or transfer costs?
  4. Use your next contract touchpoint. A new SOW, change order, capacity reservation, or renewal is a chance to narrow Force Majeure, add tech-transfer cooperation, and secure access to what you’d need to move.
  5. Start Plan B before you need it. Identify and qualify a backup CDMO while you still have time and options. A transfer started in a crisis costs more and takes longer.
  6. Put the triggers on paper. Agree with your board on what event triggers a second-source action, so you aren’t deciding mid-disruption.

Same dispute, different leverage

Now replay the scenario with a better contract. Internal labor disputes are excluded from Force Majeure. Delivery commitments are defined. At-fault failures carry real remedies: sunk costs, incremental transfer costs, and access to the know-how needed to move.

Same labor dispute. Same constrained capacity. Same small biotech. But now the CDMO has a financial reason to protect your schedule, and you have leverage if the conversation turns to moving elsewhere.

Spotting the clause isn’t the hard part

An AI review might flag labor disputes in a Force Majeure clause. But identifying a risk isn’t the same as negotiating its allocation. Someone still has to sit across from the CDMO’s lawyers, understand why they’re resisting, weigh the trade-offs, and land language the CDMO will accept.

That’s where experience matters.

We aren’t simply reviewing contracts, identifying problematic clauses, or telling clients what could go wrong.

Our expert value is in creating the environment in which favorable negotiation outcomes are achieved.

A 30-minute conversation

Danforth is offering a complimentary 30-minute call for sponsors who want to pressure-test their CDMO position. We’ll work through three questions:

  • What is your actual exposure, by program? Site, stage, inspection dependencies, and what a second-source transfer would cost in time and dollars.
  • What does your MSA give you? Force Majeure scope, notification and remediation rights, tech-transfer cooperation, step-in and termination, and what it doesn’t.
  • What’s your Plan B, and what triggers it? Clear triggers and a documented plan your board and investors can see.

No deck, no pitch. Request a call here.